Boxer Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Boxer Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-290,577	Closed	-$3.31M	–	79
2021 Q3	$3.31M	Hold	290,577	–	–	0.12%	79
2021 Q2	$4.05M	Hold	290,577	–	–	0.14%	82
2021 Q1	$5.38M	Hold	290,577	–	–	0.18%	68
2020 Q4	$5.13M	Hold	290,577	–	–	0.17%	67
2020 Q3	$4.45M	Hold	290,577	–	–	0.15%	66
2020 Q2	$7.4M	Hold	290,577	–	–	0.33%	51
2020 Q1	$4.5M	Hold	290,577	–	–	0.31%	49
2019 Q4	$3.21M	Hold	290,577	–	–	0.18%	48
2019 Q3	$2.47M	Hold	290,577	–	–	0.18%	45
2019 Q2	$3.93M	Hold	290,577	–	–	0.34%	34
2019 Q1	$5.25M	Hold	290,577	–	–	0.61%	22
2018 Q4	$8.16M	Sell	290,577 -882,123	-75%	-$18.4M	1.01%	17
2018 Q3	$29.9M	Hold	1,172,700	–	–	3.32%	12
2018 Q2	$20.3M	Buy	+1,172,700	New	+$21.2M	2.3%	16

Other funds holding KNSA

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Boxer Capital's KNSA Position: Q4 2021 in Review

Boxer Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2021, closing a stake of 290,577 shares — an estimated $3.31M sold.

Boxer Capital first reported a position in KNSA in Q2 2018 and held it in 14 quarters. The position peaked at $29.9M in Q3 2018. 103 funds tracked by Wall St. Rank hold KNSA as of Q4 2021.

Boxer Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Boxer Capital sold 290,577 Kiniksa Pharmaceuticals shares in Q4 2021, an estimated $3.31M.
Boxer Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 14 quarters.
Boxer Capital's Kiniksa Pharmaceuticals position peaked at $29.9M in Q3 2018.
103 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.